NCI National Clinical Trials Network – Network Lead Academic Participating Site

NCI 国家临床试验网络 – 网络主导学术参与站点

• 批准号: 9886223
• 负责人: LAWRENCE E FLAHERTY
• 金额: $ 50.54万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-05 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9886223
• 关键词: Adult; Advisory Committees; Affect; American College of Radiology Imaging Network; Biological Markers; Cancer Center; Cancer Research Network; Clinical Research; Clinical Trials; Colon Carcinoma; Communities; Comprehensive Cancer Center; Data; Disease; Doctor of Medicine; Doctor of Philosophy; Eastern Cooperative Oncology Group; Enrollment; Evaluation; Faculty; Foundations; Funding; Goals; Grant; Healthcare Systems; Image; Institutes; Institution; Intervention; Intervention Trial; Lead; Leadership; Malignant Neoplasms; Manuscripts; Michigan; Minority; Minority Recruitment; Monitor; National Clinical Trials Network; Organ; Parents; Patient Care; Patient Education; Patients; Phase; Play; Population; Positioning Attribute; Principal Investigator; Protocols documentation; Publications; Qualifying; Research; Research Design; Role; Safety; Science; Site; Southwest Oncology Group; System; Translations; United States; Universities; Woman; base; clinical care; expectation; meetings; melanoma; member; mortality; multidisciplinary; novel therapeutics; personalized cancer therapy; programs

Wayne State University (WSU)/ Karmanos Cancer Institute (KCI) has been an active institutional member of the cooperative group system since 1972, an NCI designated Comprehensive Cancer Center since 1978, and a parent institution Phase I (U01) since 1993. We have an active membership in the NCTN and have been an active LAPS since its inception in 2013 enrolling patients in network trials through the CTSU and using the CIRB for activation. We have enrolled over 5,500 patients onto NCTN clinical trials over the past forty years and over 250 patients have been enrolled onto interventional trials since 2014, meeting and exceeding accrual goals in a consistent manner. Since April 2014, we have opened 52 NCTN trials, including 8 Alliance, 13 ECOG-ACRIN, 17 NRG and 14 SWOG. All adult NCTN qualifying Phase II and III protocols have been submitted through the CIRB for activation since 2009. Over the years, our faculty members have played an important role in both the administrative and scientific functions of the NCTN. Since 2014, eight faculty members have held nineteen leadership positions in SWOG and ECOG-ACRIN as well as serving on NCI organ site Task Forces and Steering Committees. Since 2014, 13 faculty members have been authors or co-authors of 41 NCTN abstracts or manuscripts, and 7 faculty members have been PI or Co-PIs of 11 NCTN clinical trials. Our Cancer Center is a unique urban based center of research, patient care and education which is reflected in our recruitment of minorities (24%) and women (44%) onto intervention trials. Since our inception, the cancer programs of WSU/KCI have been organized as multidisciplinary disease programs built on the premise that multidisciplinary clinical research and care provides the best treatment option for patients with cancer. Accordingly, the translation of ideas into Network Group proposals and studies and the incorporation of NCI designated high-priority trials into the WSU/KCI treatment priorities have been easily facilitated. NCI funded trials have the highest priority for activation within our institution. Dr. Lawrence Flaherty, a SWOG member since 1988, the SWOG U-10 PI since 1996 and LAPS PI since 2013 will serve as the PI of this submission. He was the SWOG Melanoma Vice Chair from 1990 until 2011 and has been Chair of the SWOG Data Safety and Monitoring Committee since 2011. Anthony Shields, M.D., PhD. is the Project Director/Principal Investigator of the WSU/KCI LAPS serves on the NCI Colon Cancer Task Force, the ECOG-ACRIN Principal Investigator Committee, the Scientific Planning Committee, and the Nomination Committee. He is the co-chair of the Experimental Imaging Sciences Committee and the Biomarker Steering Committee.

韦恩州立大学 (WSU)/卡马诺斯癌症研究所 (KCI) 一直是该组织的活跃机构成员 自 1972 年以来的合作小组系统，自 1978 年以来被 NCI 指定为综合癌症中心，以及家长 自 1993 年以来，我们一直是 NCTN 的活跃会员，并且一直是活跃的 LAPS 该项目于 2013 年启动，通过 CTSU 招募患者参加网络试验，并使用 CIRB 进行激活。我们有 过去四十年来，NCTN 临床试验招募了超过 5,500 名患者，目前已招募超过 250 名患者 自 2014 年起进行介入试验，以一致的方式达到并超越应计目标。自2014年4月以来，我们 已开放 52 个 NCTN 试验，其中包括 8 个 Alliance、13 个 ECOG-ACRIN、17 个 NRG 和 14 个 SWOG。所有成人 NCTN 资格赛 自2009年起，II期和III期方案已通过CIRB提交激活。多年来，我们的教师 成员在 NCTN 的行政和科学职能中发挥了重要作用。自2014年以来，八 教职人员在 SWOG 和 ECOG-ACRIN 以及 NCI 机构中担任过 19 个领导职务 现场工作组和指导委员会。自 2014 年以来，13 名教职员工是 41 篇论文的作者或合著者 NCTN 摘要或手稿，7 名教员是 11 项 NCTN 临床试验的 PI 或 Co-PI。我们的癌症 中心是一个独特的城市研究、患者护理和教育中心，这反映在我们招募 少数族裔 (24%) 和女性 (44%) 参加干预试验。自成立以来，WSU/KCI 的癌症项目已 被组织为多学科疾病计划，其前提是多学科临床研究和护理 为癌症患者提供最佳的治疗选择。因此，将想法转化为网络集团 提案和研究以及将 NCI 指定的高优先级试验纳入 WSU/KCI 治疗优先事项 已经很容易地促进了。 NCI 资助的试验在我们机构内具有最高优先级激活权。劳伦斯博士 Flaherty 自 1988 年起成为 SWOG 成员，自 1996 年起成为 SWOG U-10 PI，自 2013 年起成为 LAPS PI，将担任 本次提交。 1990 年至 2011 年间，他担任 SWOG Melanoma 副主席，并一直担任 SWOG Data 主席 自 2011 年起担任安全与监测委员会。 Anthony Shields，医学博士、哲学博士。是项目总监/首席研究员 WSU/KCI LAPS 服务于 NCI 结肠癌工作组、ECOG-ACRIN 首席研究员委员会、 科学规划委员会、提名委员会。他是实验成像科学联合主席 委员会和生物标志物指导委员会。